Immunological activity for a peptide of the limulus anti-LPS factor
US6191114A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 25, 1998 |
| Grant date | Feb 20, 2001 |
| Priority date | — |
| Expiry date | Sep 25, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates a novel immunological effect of one peptide from Limulus anti-LPS factor protein. The immunological effect are, (1) induce an antiviral state in both the Hep-2 and MDBK cell lines, (2) Supernatant from human mononuclear cells stimulated with peptide Limulus anti-LPS factor (LALF) is able to induce antiviral effect on Hep-2 cell line by mean of IFN-.gamma. (3) LALF peptide is able to modulate the immune response in vitro and in vivo. The present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune responses, without stimulating the production of certain biochemical mediators (e.g., TNF-.alpha.,) that can cause detrimental effects, such as fever and inflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.